Feb 6 (Reuters) - Amerisourcebergen Corp:
* AMERISOURCEBERGEN REPORTS FISCAL 2018 FIRST QUARTER RESULTS
* Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.55 EXCLUDING ITEMS
* REVENUES OF $40.5 BILLION FOR Q1, A 6.0 PERCENT INCREASE YEAR-OVER-YEAR
* AMERISOURCEBERGEN - ADJUSTED EARNINGS PER SHARE BENEFIT FROM U.S. TAX REFORM IS EXPECTED TO BE ABOUT $0.60 IN FISCAL 2018
* SEES 2018 ‍ADJUSTED DILUTED EARNINGS PER SHARE TO BE IN RANGE OF $6.45 TO $6.65​
* SEES 2018 ‍REVENUE GROWTH IN RANGE OF 8 PERCENT TO 11 PERCENT​
* AMERISOURCEBERGEN - “REMAIN CONFIDENT IN PHARMEDIUM’S ABILITY TO RETURN TO ITS LONG-TERM GROWTH TRAJECTORY”
* SEES 2018 ‍CAPITAL EXPENDITURES OF APPROXIMATELY $325 MILLION​
* Q1 EARNINGS PER SHARE VIEW $1.35, REVENUE VIEW $40.50 BILLION — THOMSON REUTERS I/B/E/S
* FY2018 EARNINGS PER SHARE VIEW $6.29, REVENUE VIEW $166.80 BILLION — THOMSON REUTERS I/B/E/S
* AMERISOURCEBERGEN - CONTINUES TO OPERATE UNDER ASSUMPTION THAT BRAND DRUG INFLATION WILL BE IN RANGE OF 6 PERCENT TO 7 PERCENT FOR PHARMACEUTICAL MARKET IN 2018
* AMERISOURCEBERGEN - CONTINUES TO OPERATE UNDER ASSUMPTION THAT GENERIC DRUG DEFLATION WILL BE IN RANGE OF -7 PERCENT TO -9 PERCENT FOR PHARMACEUTICAL MARKET IN 2018 Source text for Eikon: Further company coverage: